{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:01:39Z","timestamp":1648774899174},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6,15]]},"DOI":"10.2146\/news110038","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T15:46:55Z","timestamp":1307116015000},"page":"1059-1059","source":"Crossref","is-referenced-by-count":1,"title":["Linagliptin approved for type 2 diabetes"],"prefix":"10.1093","volume":"68","author":[{"given":"Kate","family":"Traynor","sequence":"first","affiliation":[]}],"member":"286","container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/12\/1059\/28349523\/ajhp1059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T21:44:58Z","timestamp":1555019098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/12\/1059\/5129363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,15]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,6,15]]}},"URL":"https:\/\/doi.org\/10.2146\/news110038","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,6,15]]},"published":{"date-parts":[[2011,6,15]]}}}